



DNAe Appoints International Infectious Disease Experts to its Newly Formed Clinical Advisory Board

Founding CAB members are Professor Paul Dark, Professor Angela Caliendo, Professor Stephan Harbarth and Professor Romney Humphries

London, UK and Carlsbad, CA, USA – 7 March 2017 – DNA Electronics ('DNAe'), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary blood-to-result test for bloodstream infections, announces the formation of its clinical advisory board (CAB). The CAB, with founding members Professor Paul Dark, Professor Angela Caliendo, Professor Stephan Harbarth and Professor Romney Humphries, brings together US and European experts to provide strategic guidance for the clinical development of DNAe's diagnostic platform, LiDia™, and its accompanying range of tests for different clinical applications.

"As we continue the commercialization of our technology and prepare for the launch of our first product, the LiDia™ Bloodstream Infection (BSI) Test, it is important that we work closely with experts to ensure that our products are aligned with hospital practice and best serve the medical need" said Dr Steve Allen, CEO of DNAe Group Holdings.

Regius Professor Chris Toumazou, FRS, FREng, FMedSci, Founder and Executive Chairman of DNAe Group Holdings added: "The members of our new Clinical Advisory Board are each highly esteemed in their respective fields. They bring a range of expertise and clinical specialisms including clinical microbiology, sepsis, point-of-care diagnostics, critical care and hospital epidemiology, providing a perfect fit to our work in developing fast and powerful genomic tests for infectious diseases. We welcome their critical contribution to our product development and are confident they will contribute positively to our mission to bring cutting edge near-patient technology to the early diagnosis and monitoring of life threatening diseases."

The board is formed of the following distinguished academic clinicians:

Professor Paul Dark, BSc, MD, PhD, FRCS, FRCER, FFICM

Professor Dark is Chair of Critical Care Medicine at the University of Manchester, UK, where he is responsible for developing postgraduate learning in research and innovation in acute healthcare. He is a senior clinical academic at the University, carrying out his duties as an NHS consultant in Critical Care Medicine at the Salford Royal NHS Foundation Trust. He is also a National Research Lead in Critical Care for the National Institute of Health Research (NIHR) and Visiting Professor at King's College London. He leads a program of work funded by the NIHR, developing and assessing the diagnostic utility of emerging molecular technologies in the setting of sterile tissue injury and severe infection - focused on matrices in blood and breath. He has also led a program funded by Innovate UK, developing novel technologies aimed at rapid point-of-care infection/sepsis diagnosis. He advises NICE on diagnostic technology appraisals in sepsis and leads multi-center pragmatic clinical trials aimed at developing an improved evidence base for the management sepsis.

Professor Angela Caliendo, MD, PhD, FIDSA

Dr Caliendo is Professor, Executive Vice Chair of the Department of Medicine, and Director of the Division of General Internal Medicine at the Warren Alpert Medical School of Brown University, USA. She is an Editor for the Journal of Clinical Microbiology, Chair of the Microbiology Medical Devices Panel for the FDA and was Chair of the Diagnostics Task Force for the Infectious Diseases Society of America and is currently on the Board of Directors for the Infectious Diseases Society of America. Dr. Caliendo's research has focused on the development of molecular diagnostic tests for the detection and quantification of infectious diseases and assessment of their clinical utility.

Professor Stephan Harbarth, MD, MS

Dr Stephan Harbarth is Associate Professor the University of Geneva, Switzerland and Senior Consultant at Geneva University Hospitals. His group is currently conducting several clinical and epidemiological studies to evaluate key questions related to the control of the acquisition, transmission and infection by multidrug-resistant microorganisms. It is also participating in several ongoing large-scale EU-funded studies to address this public health threat and collaborating closely with the Genomics Research Laboratory at HUG (University of Geneva Hospitals), based on a productive translational research platform.

Professor Romney Humphries, PhD, D(ABMM), M(ASCP)^{CM}

Dr Humphries is an Assistant Professor in the Department of Pathology and Laboratory Medicine in the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), USA. She is the Section Chief for Clinical Microbiology at UCLA Health and Chief Quality Officer for the Department of Pathology & Laboratory Medicine. Dr Humphries' research focus is the detection and characterization of emerging antimicrobial resistance in bacteria, and the development of next generation diagnostic technologies. She is a member of the Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing (AST) Subcommittee and Microbiology Resource Committee for the College of American Pathologists.

—Ends—

About DNAe – www.dnae.com

DNAe is commercializing its pioneering semiconductor DNA sequencing technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.

In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics Inc.), a developer of a novel system for rapid isolation of rare cells in the bloodstream. DNAe is developing LiDia™, its sample-to-result genomic analysis platform, combining DNA Electronics Inc.'s Pathogen Capture System with its own portfolio of semiconductor-based genomic technologies, trademarked Genalysis®. The LiDia™ range of tests will enable DNA analysis directly on a microchip, providing rapid and accurate results from a user-friendly system.

DNAe's initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. LiDia™ launches with the LiDia™ Bloodstream Infection (BSI) test, a groundbreaking rapid direct-from-specimen test for bloodstream infections that lead to sepsis. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

In October 2016, the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) awarded DNAe a contract worth up to \$51.9 million to develop Genalysis® for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza.

A private company, with bases in London, UK and Carlsbad, CA, USA, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting-edge life sciences companies.

Contact Details

DNAe

Dr Steve Allen, Chief Executive Officer, DNAe Group

Tel: +44 (0)20 7036 2100

Victor Esch, President and Chief Executive Officer, DNA Electronics

Tel: +1 (760) 444-9410

Inc.

Instinctif Partners (media relations)

Sue Charles / Alex Bannister / Deborah Bell

Tel: +44 (0)20 7457 2020

Email: DNAe@instinctif.com